Dr. Kobayashi is an accomplished executive scientist and President of AkeOla LLC. She has a deep knowledge of and experience in drug development activities for rare diseases, including drug screening, biomarker development and regulatory strategy that spans nearly 20 years. Prior to founding AkeOla, Dr. Kobayashi worked as an executive scientist in several biotech and pharmaceutical companies as well as non-profit organizations including Cydan Development, Alector, the Spinal Muscular Atrophy Foundation, Rinat (a subsidiary of Pfizer), Elan Pharmaceuticals, and Genentech. She has published various journal articles focused in neurodegenerative, neurodevelopment, neuromuscular, and ocular rare genetic diseases.
Dr. Kobayashi received her BSci in Brain and Cognitive Science from MIT, MSci in Cell, Molecular and Neurosciences from University of Hawaii Manoa, and her PhD in Neuroscience from the University of Edinburgh. She is a member of the Cure CMD Scientific Advisory Board (SAB), the Bluefield Project to Cure Frontotemporal Dementia Internal Advisory Board, and the Myonexus Therapeutics SAB.